Browse by author
Lookup NU author(s): Dr Louise Robinson
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseOver the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with Alzheimer's disease has increased. Although these pharmacological and non-pharmacological strategies have significantly improved health outcomes for patients with Alzheimer's disease, many lack stringent evidence of efficacy. In this second paper of the Series, we provide practical and realistic advice on how to prioritise pharmacological and non-pharmacological strategies to ameliorate cognitive impairment and behavioural and psychological symptoms of dementia. In this clinical environment, dementia specialists are faced with the challenge of holistically integrating the much anticipated and, in some respects, controversial anti-β amyloid monoclonal antibodies. Here, we present the current approval scenario of monoclonal antibodies, our view on how they might further contribute to improve patients' quality of life, and how they could be seamlessly integrated with existing best care options.
Author(s): Fox NC, Belder C, Ballard C, Kales HC, Mummery C, Caramelli P, Ciccarelli O, Frederiksen KS, Gomez-Isla T, Ismail Z, Paquet C, Petersen RC, Perneczky R, Robinson L, Sayin O, Frisoni GB
Publication type: Review
Publication status: Published
Journal: The Lancet
Year: 2025
Volume: 406
Issue: 10510
Pages: 1408-1423
Online publication date: 22/09/2025
Acceptance date: 02/04/2018
ISSN (print): 0140-6736
ISSN (electronic): 1474-547X
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/S0140-6736(25)01329-7
DOI: 10.1016/S0140-6736(25)01329-7
PubMed id: 40997839
